FILTERED RESULTS
FILTERS
Ads Top
DARK MODE
CHART
    Filters
      Symbols
      Sentiment
      Impact
      Search
      FILTERED RESULTS

        

      Upgrade your plan
      ·

      abbvpfe

      ·

      AbbVie and Pfizer Report Divergent Earnings in Fourth Quarter

      AbbVie and Pfizer, two major players in the pharmaceutical industry, released their fourth-quarter earnings in early February, highlighting contrasting trajectories for both companies. AbbVie is experiencing a resurgence following the expiration of Humira's patent, with its new drug Skyrizi playing a significant role in this transformation. In contrast, Pfizer is still navigating the aftermath of its COVID-19 vaccine success and is in search of a sustainable growth strategy beyond its pandemic-related products.

      For investors focused on dividends, the differences between the two companies are pronounced. AbbVie offers a more attractive dividend yield, which is bolstered by its successful product pipeline and strategic reinvention. Meanwhile, Pfizer's dividend appeal is diminished as it continues to adjust its portfolio away from COVID-related revenues, which have been a major contributor to its earnings in recent years. This divergence in growth strategies and dividend sustainability presents a clear choice for investors in the pharmaceutical sector.

      © 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

      Source: KLEA News

      .

      Terra Founder Do Kwon Sentenced to 15 Years in Prison for Fraud